Gyre Therapeutics is trading 5.9% lower at $4.45, with no confirmed company-specific or broader-market cause established.
- The decline follows the sharp drop on October 30.
- Available searches found no confirmed company-specific announcement; the investor-relations page lists second-quarter 2026 results, not a November 3 catalyst.
- Biotech was reported higher during the session, so the sector trend does not explain the decline.